Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)

Polyarticular Juvenile Idiopathic Arthritis Clinical Trial

Official title:
An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety, Efficacy and PK of MRA in Patients With pJIA Who Participated in Study MRA318JP

Status Completed

Clinical Trial Summary

This is an open-label, extension, Phase III study to evaluate the long-term safety, efficacy and PK of MRA in patients with pJIA who participated in Study MRA318JP.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Arthritis
Arthritis, Juvenile
Polyarticular Juvenile Idiopathic Arthritis

Clinical Trial Details

NCT number	NCT00144625
Study type	Interventional
Source	Chugai Pharmaceutical
Contact
Status	Completed
Phase	Phase 3
Start date	February 2005
Completion date	June 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05411211` - An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Completed	`NCT02141984` - Surveillance of Humira in Korean JIA Patients	N/A
Completed	`NCT04018599` - Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS	Phase 1
Active, not recruiting	`NCT05754710` - Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis